PFE Pfizer Inc.

41.67
+0.08  (+0%)
Previous Close 41.59
Open 41.71
Price To Book 3.94
Market Cap 231682249347
Shares 5,559,929,190
Volume 27,310,300
Short Ratio 3.16
Av. Daily Volume 23,204,166

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated in 2018.
Yescarta (Axicabtagene Ciloleucel) and Utomilumab (PF-05082566)
Large B-Cell Lymphoma
Phase 3 data released May 15, 2019 met primary endpoints.
PF-04965842 - abrocitinib
Moderate-to-severe atopic dermatitis (AD)
Approval announced December 13, 2017.
IXIFI
Remicade (infliximab) biosimilar
Phase 3 data released November 28, 2017 - primary endpoint not met.
Avelumab
Gastric cancer
Approval announced October 12, 2017.
LYRICA (pregabalin)
Postherpetic neuralgia (PHN)
Advisory Committee Meeting held November 7, 2017. No votes cast.
Staphylococcus aureus vaccine
Phase 3 data presented at ESMO 2017 - Overall survial HR=0.760 (p=0.09)
XALKORI (crizotinib)
ALK-positive advanced non-small cell lung cancer(NSCLC)
Approval announced September 1, 2017.
Mylotarg (gemtuzumab ozogamicin)
Acute myeloid leukemia (AML)
CRL issued June 22, 2017.
Epoetin alfa biosimilar
FDA approval announced November 2, 2018.
Lorlatinib
ALK+ NSCLC
Approval announced May 9, 2017.
Avelumab
Urothelial Carcinoma
Approval announced August 17, 2017.
Inotuzumab Ozogamicin
Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults
Phase 3 trial met primary endpoint - December 20, 2018.
XTANDI (ARCHES)
Metastatic hormone sensitive prostate cancer
Phase 3 trial terminated - noted May 17, 2017.
XTANDI (ENDEAR)
Triple negative breast cancer
Phase 3 data due 2H 2020.
XTANDI (EMBARK)
Non-metastatic high risk hormone-sensitive prostate cancer
FDA approval announced July 13, 2018.
XTANDI (PROSPER)
Non-metastatic high risk hormone-sensitive prostate cancer
Approval announced May 30, 2018.
Xeljanz
Ulcerative colitis
Approval announced December 14, 2017.
Xeljanz
Psoriatic arthritis
FDA Approval announced October 16, 2018.
Talazoparib
BRCA-mutated breast cancer
Approval announced 16 November, 2017.
Sutent (Sunitinib)
Renal cell carcinoma (RCC)
Phase 3 trial met primary endpoint - December 2016.
LYRICA (pregabalin)
Pediatric Epilepsy
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Approval announced December 19, 2017.
BOSULIF (BOSUTINIB)
First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia
Priority review announced November 29, 2016. Approval announced March 23, 2017.
Avelumab
Metastatic Merkel cell carcinoma
sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.
IBRANCE (palbociclib)
HR+, HER2- Metastatic Breast Cancer
Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.
Tanezumab
Chronic low back pain
Phase 3 data from second trial released January 29, 2019 - co-primary endpoints met. Data from trial April 18, 2019 met 2/3 primary endpoints in 5mg arm but failed to meet endpoints in 2.5mg arm.
Tanezumab
Osteoarthritis
Phase 3 ongoing.
Tanezumab
Cancer pain
Phase 3 data due 2H 2019.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease
Approved Sept 10 2014
XTANDI
Cancer - mCRPC who have not received chemotherapy
FDA Approval announced May 6, 2019.
Tafamidis (tafamidis free acid form)
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA Approval announced September 27, 2018.
Dacomitinib
Non-small cell lung cancer (NSCLC)
BsUFA date 3Q 2019.
PF-05280586 (Biosimilar to Rituxan/ MabThera)
CD20-positive, low tumor burden, follicular lymphoma
Phase 3 trial discontinued due to futility.
INLYTA (axitinib)
Recurrent renal cell carcinoma (RCC)
Phase 1b data due at PPMD Annual Conference, June 26-30, 2019
PF-06939926
Duchenne muscular dystrophy (DMD)
Phase 3 overall survival secondary endpoint not met - June 25, 2018. PFS primary endpoint met (announced previously).
IBRANCE - PALOMA-3
Breast cancer
Phase 3 presentation at ASCO June 2018.
IBRANCE (palbociclib)
Head and neck squamous cell carcinoma
FDA approval announced November 21, 2018.
Glasdegib
Acute myeloid leukemia (AML)
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B
Phase 2 development terminated due to lack of efficacy.
Domagrozumab
Duchenne muscular dystrophy (DMD)
FDA Approval announced May 14, 2019.
BAVENCIO (avelumab) and INLYTA (axitinib)
Renal cell carcinoma (RCC)
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
BsUFA date 2Q 2019.
PF-06439535
Biosimilar bevacizumab
FDA Approval March 11, 2019.
PF-05280014 TRAZIMERA
Herceptin biosimilar
Phase 3 trial to be terminated due to lack of efficacy.
Avelumab - JAVELIN Ovarian 100
Ovarian cancer
Phase 3 data due 2H 2021.
PF-06651600 - JAK3
Alopecia areata
FDA approval announced May 6, 2019.
Tafamidis
Transthyretin amyloid cardiomyopathy (ATTR-CM)
FDA approval of sNDA announced April 4, 2019.
IBRANCE (palbociclib)
HR+/HER2- advanced breast cancer in men
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PENELOPE
Early stage breast cancer
Phase 3 data due 2H 2020.
IBRANCE (palbociclib) - PALLAS
Early stage breast cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Gastric cancer
Phase 3 data due 1H 2020.
Avelumab - Bavencio
Urothelial Cancer
Phase 3 data due 2H 2020.
PF-06425090
C. difficile Infection